« Go Back

David Allison, Ph.D.

Dr. Allison joined Westlake BioPartners as a Managing Director in 2023 from 5AM Ventures where he was a Partner for over 6 years. During his time at 5AM, he was involved in the firm’s investments in CinCor Pharma (acquired by AstraZeneca), Crinetics (NASDAQ: CRNX), Impel Neuropharma (NASDAQ: IMPL), Inipharm, Magnetic Insight, Neurogastrx, Portal Instruments, and Radionetics. Prior to 5AM, Dr. Allison was a Principal at Versant Ventures and spent time on the healthcare team at Split Rock Partners and PTV Healthcare Capital. Dr. Allison received a Ph.D. in Bioengineering from Rice University and a B.S.E in Biomedical Engineering from The University of Iowa.